Market
First major market to approve Trodelvy for NSCLC with EGFR mutations by end of 2025
2
Resolution / Starting Odds
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
Official health regulatory agency announcements
Story
FDA Grants Breakthrough Therapy Designation to Trodelvy for Advanced NSCLC and Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024, 01:36 PM
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to sacituzumab tirumotecan, also known as Trodelvy, for the treatment of advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutations that have progressed after treatment with a tyrosine kinase inhibitor (TKI) and chemotherapy. This designation is significant for Gilead Sciences, as it enhances the potential for expedited development and review of the therapy. Additionally, the FDA has also recognized Trodelvy for use as a second-line treatment for extensive-stage small cell lung cancer, marking another important milestone for the drug's application in oncology.
View original story
Similar markets
Third • 25%
Leading • 25%
Lower • 25%
Second • 25%
No Approval • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Yes • 50%
No • 50%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%
Significant Improvement • 25%
Roche • 25%
AstraZeneca/Daiichi Sankyo • 25%
Other • 25%
Pfizer • 25%
China • 25%
United States • 25%
Other • 25%
European Union • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Canada • 25%
Other • 25%
Japan • 25%
European Union • 25%